webinar recording available - register to watch

A new class of startups is scouting for deals - on both sides of the Pacific

It used to be that executing a global strategy meant finding a partner for the European market. Now, China has completely changed the way the world works. Startups have been in-licensing for years in a growing set of diseases. And now they are outlicensing to the US and Europe. What happens as more sophisticated R&D organizations go after novel drug targets? Lets find out.

watch now
watch the webinar

No cost to register, subject to confirmation

By registering for this event, you accept that you may receive direct communication from the sponsor(s).

If you are experiencing problems with your registration, please try the Zoom registration page.

Petter Veiby

Petter Veiby

Head of Alliance Management, Search & Evaluation for Business Development, Zai Lab

With more than 25 years of experience in the biopharmaceutical industry, Petter Veiby is currently the Head of Alliance Management and Search & Evaluation at Zai Lab. Prior to joining Zai, he was Head of Alliances and New Ventures for Oncology and Immunology at Takeda Pharmaceuticals. In this role, he led several external innovation initiatives including strategic academic alliances as well as biotech and pharma collaborations. Prior to this role he was the global head of Biotherapeutics for oncology and earlier in his career with Takeda and Millennium Pharmaceuticals, he held various leading drug discovery roles and was a senior member of Takeda’s oncology drug discovery unit. During this time, he led numerous programs through discovery and into the clinic. Petter was educated at the University of Oslo in Norway before moving to the US for post-doctoral training and joined his first Biotech in 1992.

Christian Hogg

Christian Hogg

CEO and Executive Director of HUTCHMED, HUTCHMED

Mr. Hogg has been the CEO and Executive Director of HUTCHMED since 2006. He is also a member of the Technical Committee of HUTCHMED. He joined the business in 2000, as its first employee, and has since led the creation and management of its strategy, business and listings. This includes the establishment of the Oncology/Immunology operations, which now comprise 11 drug candidates that are in clinical studies globally and a scientific team of over 740 people. Mr. Hogg oversaw the acquisition and integration of assets forming the Other Ventures, which manufacture, market, and distribute prescription drugs and consumer health products, covering an extensive hospital network across China.

Prior to joining the Company, Mr. Hogg spent ten years with P&G in the U.S., China, and Brussels.

Mr. Hogg received a Bachelor’s degree in Civil Engineering from the University of Edinburgh and a Master's in Business Administration from the University of Tennessee.

Angus Grant

Angus Grant

Chief Business Executive, BeiGene

Angus Grant, Ph.D., joined BeiGene in June 2020 as Chief Business Executive, bringing in more than 25 years of experience across multiple key functions in the biotech industry, including business development, alliance management, research and development, and regulatory affairs . In this role, Dr. Grant oversees corporate strategy, business development, and alliance management, and helps drive external innovation and investment in other companies to guide BeiGene’s global growth strategy. Prior to joining us, Dr. Grant was the CEO of the Dementia Discovery Fund (DDF), a specialist venture capital fund focused on therapeutics for age-related dementias and neurodegenerative disease. Before that, Dr. Grant spent 12 years at Celgene (now a Bristol Myers Squibb company) serving various executive roles, including Corporate Vice President of Business Development and Vice President, Regulatory Affairs. Earlier in his career, Dr. Grant worked in business development and regulatory roles at Novartis, Merck KGaA, Rhone Poulanc-Rohrer, SmithKline Beecham, and the U.S. Food and Drug Administration’s Center for Biologics. He currently serves as the Chairman of the Board for Toronto Innovation and Acceleration Partners. Dr. Grant received a bachelor’s degree from the University of Richmond and a Ph.D. in Anatomy and Immunology from the Medical College of Virginia and completed his postdoctoral training at the National Cancer Institute.

Michelle Chen

Michelle Chen

Chief Business Officer, Insilico Medicine

Dr. Michelle Chen is the Chief Business Officer of Insilico Medicine. She brings more than 20 years of extensive experience in both the biopharma and technology industries. Prior to Insilico Medicine, she was the Senior Vice President of Corporate Development for WuXi Biologics where she led multiple M&A and licensing transactions, drove strategic partnerships with external biopharma partners, and represented the company at various investor conferences. As a biotech executive, Dr. Chen has worked at top pharmaceutical companies such as Roche, Merck, and BioMarin, as well as biotech and technology companies in roles ranging from business and corporate development, product marketing, and R&D with a strong track record of success. She has a Ph.D. in Biochemistry from the University of Washington, did postdoctoral work at the University of California San Francisco, and received Bioinformatics training at Stanford University.

Kyle Blankenship
moderator

Kyle Blankenship

Managing Editor, Endpoints News

A native of Austin, Kyle previously worked as an associate editor at another leading biopharma publication and has held editor roles at two daily newspapers in Texas. In addition to a bachelor’s degree from Texas A&M University, Kyle holds a master’s degree in journalism from the University of North Texas in Denton. At Endpoints, Kyle leads the company’s manufacturing coverage as well as running point on virtual events, editing and content strategy. An avid cook and history nerd, you can find Kyle hovering over the stove—spatula in one hand and a World War II tome in the other.